期刊文献+

罗格列酮抑制糖基化-人白蛋白诱导的人单核细胞源树突状细胞的免疫成熟 被引量:2

Rosiglitazone inhibits advanced glycosylation end-human serum albumin induced immune maturation of dendritic cells
下载PDF
导出
摘要 目的:研究过氧化物酶体增殖物激活受体-γ(PPAR-γ)激动剂罗格列酮(rosiglitazone)对糖基化终产物(AGEs)诱导的人单核细胞源树突状细胞(DC)的免疫成熟的影响。方法:采用免疫磁珠法分离人外周血CD14+单核细胞,经含重组人粒细胞—巨噬细胞集落刺激因子(GM-CSF,100μg/L)和重组人白细胞介素4(IL-4,20μg/L)的RPMI1640培养5天,使其分化为未成熟DC。先经罗格列酮(50μmol/L)干预24h后,加入糖基化-人血清白蛋白(AGE-HSA,200μg/ml)再干预48h,采用流式细胞术检测树突状细胞表型(CD1a、CD80、CD86和HLA-DR),混合T淋巴细胞反应检测DC对淋巴细胞增殖的影响,酶联免疫吸附法检测细胞培养上清白细胞介素10(IL-10)、白细胞介素12(IL-12)、肿瘤坏死因子α(TNF-α)和γ干扰素(INF-γ)的浓度。结果:与对照组相比,经罗格列酮处理的DC可明显下调由AGE-HSA促进的CD80、CD86、HLA-DR和CD1a的表达,使AGE-HSA促进的对T淋巴细胞的增殖作用明显减弱,明显抑制DC细胞因子IL-10、IL-12、TNF-α和IFN-γ的分泌(P<0.05)。结论:过氧化物酶体增殖物激活型受体γ激动剂罗格列酮可以抑制糖基化-人血清白蛋白诱导的树突状细胞的免疫成熟及其免疫功能,这可能是它抗炎的重要机制之一。 Objective:To investigate the effect of peroxisome proliferator activated receptors-γ(PPAR-γ) agonist Rosiglitazone on the immune maturation of monocyte-derived dendritic cell(DC) induced by advanced glycosylation end products(AGEs). Methods:Monocytes were purified(over 98%) using Anti-CD14 microbeads. After cultured with DC Cellgro medium containing recombinated human granulocyte-macrophage colony stimulating factor(rhGM-CSF)(100 μg/L) and recombinated human interleukin-4(rhIL-4)(20 μg/L) for 5 days,monocytes were derived into immature DC. Rosiglitazone(50 μmol/L) was added to the medium for 24 hours. The advanced glycosylation end-human serum albumin(AGE-HSA)(200 μg/ml) was then added to the medium for another 48 hours. The expressions of(CD1a,CD80,CD86 and HLA-DR) were analyzed by FACS,and the cytokines secretions of culture supernatants(IL-10,IL-12,TNF-α and INF-γ) were measured by ELISA. Results:Rosiglitazone reduced AGE-HSA inducing expressions of CD1a,CD80,CD86 and HLA-DR,and also inhibited AGE-HSA inducing T-cell stimulatory activity. The cytokines secretions of DCs induced by AGE-HSA were significantly attenuated by Rosiglitazone. Conclusion:The study suggested that one of the anti-inflammatory mechanisms of PPAR-γ agonist Rosiglitazone should be mediated by inhibiting the AGEs induced maturation and immune function of DCs.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2008年第6期767-770,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省医学领军人才基金资助
关键词 树突状细胞 动脉粥样硬化 糖基化-人血清白蛋白 罗格列酮 过氧化物酶体增殖物激活受体Γ dendritic cells atherosclerosis AGE-HSA Rosiglitazone peroxisome proliferator-activated receptor gamma
  • 相关文献

参考文献14

  • 1Goldin A,Beckman JA,Schmidt AM,et al.Advanced glycation end products:sparking the development of diabetic vascular injury[J].Circulation,2006,114:597-605.
  • 2Yan SF,D' Agate V,Schmidt AM,et al.Receptor for advanced glycation endproducts (RAGE):a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging[J].Curr Mol Med,2007,7 (8):699-710.
  • 3Nasser A,Grozny JJ,Weygand CM.Immune-mediated mechanisms in atherosclerosis:prevention and treatment of clinical manifestations[J].Curr Pharm Des,2007,13(36):3701-3710.
  • 4梁春,罗育坤,王克强,贾剑国,黄东,葛均波,钟翠平,苏敏,张新华,顾云娣.血管树突状细胞在人主动脉粥样硬化早期病变中的分布[J].解剖学杂志,2003,26(3):222-225. 被引量:17
  • 5Li J,Wang N.Peroxisome proliferator-activated receptorgamma in vascular biology[J].Cardiovasc Hematol Disord Drug Targets,2007,7 (2):109-117.
  • 6Ge J,Jia Q,Liang C et al.Advanced glycosylation endproducts might promote atherosclerosis through inducing the immune maturation of dendritic-cells[J].Arterioscler Thromb Vase Biol,2005,25(10):2157-2163.
  • 7贾庆哲,葛均波,梁春,罗育坤,黄东,王克强,陈灏珠.糖基化终产物对人单核细胞源树突状细胞糖基化终产物受体表达的研究[J].中国病理生理杂志,2006,22(1):139-142. 被引量:3
  • 8Sharma AM,Staels B,Review:Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism[J].J Clin Endocrinol Metab,2007,92 (2):386-395.
  • 9Gerry JM,Pascual G.Narrowing in on cardiovascular disease:the atheroprotective role of peroxisome proliferator-activated receptor gamma[J].Trends Cardiovasc Med,2008,18(2):39-44.
  • 10Molavi B,Rassouli N,Bagwe S,et al.A review of thiazolidinediones and metformin in the treatmentof type 2 diabetes with focus on cardiovascular complications[J].Vasc Health Risk Manag,2007,3 (6):967-973.

二级参考文献18

  • 1Ross R.Atherosclerosis-an inflammatory disease[ J].N Engl J Med,1999,340(2):115-126.
  • 2Hansson GK.Immune mechanisms in atherosclerosis[J].Arterioscler Thromb Vasc Biol,2001,21(12):1876-1890.
  • 3Bobryshev YV,Lord RS.Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions[J].Cardiovasc Res,1998,37(3):799-810.
  • 4Kume S,Takeya M,Mori T,et al.Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody[J].Am J Pathol,1995,147(3):654-667.
  • 5Cipollone F,Iezzi A,Fazia M,et al.The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques:role of glycemic control[J].Circulation,2003,108(9):1070-1077.
  • 6Wick G,Perschinka H,Millonig G.Atherosclerosis as an autoimmune disease:an update[J].Trends Immunol,2001,22(12):665-669.
  • 7Aicher A,Heeschen C,Mohaupt M,et al.Nicotine strongly activates dendritic cell-mediated adaptive immunity:potential role for progression of atherosclerotic lesions[J].Circulation,2003,107(4):604-611.
  • 8Alderman CJ,Bunyard PR,Chain BM,et al.Effects of oxidised low density lipoprotein on dendritic cells:a possible immunoregulatory component of the atherogenic micro-environment? [J].Cardiovasc Res,2002,55(4):806-819.
  • 9Luo YK,Liang Ch,Huang D,et al.Foam cell can be induced oxidized low density lipoprotein in human monocytederived dendritic cells:A new source of foam cell in atherogenesis[J].Circulation(supplement Ⅳ),2003,108(17):202.
  • 10Zhang L,Zalewski A,Liu Y,et al.Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries[J].Circulation,2003,108(4):472-478.

共引文献18

同被引文献21

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部